Evommune Inc. is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases. Evommune Inc. is based in PALO ALTO, Calif.
| Revenue (Most Recent Fiscal Year) | $13.00M |
| Net Income (Most Recent Fiscal Year) | $-68.87M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.95 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -946.68% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -62.63% |
| Return on Assets (Trailing 12 Months) | -40.55% |
| Current Ratio (Most Recent Fiscal Quarter) | 11.68 |
| Quick Ratio (Most Recent Fiscal Quarter) | 11.68 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $7.65 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.89 |
| Earnings per Share (Most Recent Fiscal Year) | $-11.22 |
| Diluted Earnings per Share (Trailing 12 Months) | $-11.03 |
| Exchange | NYSE |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 36.29M |
| Free Float | 25.00M |
| Market Capitalization | $544.74M |
| Average Volume (Last 20 Days) | 0.49M |
| Beta (Past 60 Months) | -- |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 31.10% |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |